The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Samartsev I.N.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Zhivolupov S.A.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Nazhmudinov R.Z.

Elizaveta Hospital, St. Petersburg, Russia

Identification of non-steroidal anti-inflammatory drugs as a necessity basis of effectiveness and risk correlation conception

Authors:

Samartsev I.N., Zhivolupov S.A., Nazhmudinov R.Z.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12): 124‑131

DOI: 10.17116/jnevro2019119121124

Read: 22047 times

Download PDF (RU)
Contact the author
Table of contents

IDENTIFICATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AS A NECESSITY BASIS OF EFFECTIVENESS AND RISK CORRELATION CONCEPTION
IDENTIFICATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AS A NECESSITY BASIS OF EFFECTIVENESS AND RISK CORRELATION CONCEPTION

To cite this article:

Samartsev IN, Zhivolupov SA, Nazhmudinov RZ. Identification of non-steroidal anti-inflammatory drugs as a necessity basis of effectiveness and risk correlation conception. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12):124‑131. (In Russ.)
https://doi.org/10.17116/jnevro2019119121124

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Control of neuropathic pain in lumbosacral dorsalgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):152-157
Open obse­rvational study with a retrospective analysis of the effi­cacy and tole­rability of aceclofenac in patients with acute non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):99-105
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Effi­cacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79
Effe­ctiveness of spinal traction in dege­nerative spine diseases. (A lite­rature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(4):60-69
Dete­rmination of factors influencing the medi­cal checkups effe­ctiveness of adult popu­lation living in rural areas. Russian Journal of Preventive Medi­cine. 2024;(10):23-28
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80
Pharmacological pain mana­gement in pediatric inte­nsive care. Russian Journal of Pain. 2025;(1):56-61
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for treatment of pain, fever and inflammatory diseases. However, along with a high rate of efficacy, NSAIDs have been associated with an increased risk of gastrointestinal and cardiovascular complications related to the inhibition of the enzymes cyclooxygenase 1 and 2. The review addresses contemporary mechanisms of NSAID’s side-effects and analyzes clinical trials of the efficacy and tolerability of aceclofenac, which is the most frequently prescribed NSAID, as in its traditional release form (100 mg 2 times a day) as well as in the controlled-release (200 mg a day) form.

Keywords:

non-steroidal anti-inflammatory drugs (NSAIDs)
efficacy
side-effects
aceclofenac

Authors:

Samartsev I.N.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Zhivolupov S.A.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Nazhmudinov R.Z.

Elizaveta Hospital, St. Petersburg, Russia

List of references:

  1. Reid K, Harker J, Bala M, Truyers C, Kellen E, Bekkering G, Kleijnen J. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Current Medical Research and Opinion. 2011;27:449-462. https://doi.org/10.1185/03007995.2010.545813
  2. Insitute of Medicine. Relieving pain in America. A Blueprint for transforming prevention, care, education and research. The National Academies Press. 2011.
  3. Murthy VH. Ending the opioid epidemic — a call to action. The New England Journal of Medicine. 2016;375:2413-2415. https://doi.org/10.1056/NEJMp1612578
  4. Zhou Y, Boudreau D, Freedman A. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014;23:43-50. https://doi.org/10.1002/pds.3463
  5. Walker L, Zambraski E, Williams R. Widespread use of prescription nonsteroidal anti-inflammatory drugs among U.S. army active duty soldiers. Military Medicine. 2017;182:1709-1712. https://doi.org/10.7205/MILMED-D-16-00183
  6. Gorski T, Cadore E, Pinto S, da Silva E, Correa C, Beltrami F, Kruel L. Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use. British Journal of Sports Medicine. 2011;45:85-90. https://doi.org/10.1136/bjsm.2009.062166
  7. Sondergaard K, Gislason G. NSAIDs and cardiac arrest: Non-steroidal anti-inflammatory drug use is associated with increased risk of Out-of-hospital Cardiac Arrest: A nationwide Case-Time-Control study. European Heart Journal. 2017;38:1788-1789. https://doi.org/10.1093/eurheartj/ehx267
  8. Bjorkman D. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. The American Journal of Medicine. 1999;107:3-8. https://doi.org/10.1016/s0002-9343(99)00362-9
  9. Bresalier R, Sandler R, Quan H, Bolognese J, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam M, Baron J. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The New England Journal of Medicine. 2005;352:1092-1102. https://doi.org/10.1056/NEJMoa050493
  10. Solomon S, Pfeffer M, McMurray J, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber A, Bertagnolli M, Arber N, Wittes J. APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028-1035. https://doi.org/10.1161/CIRCULATIONAHA.106.636746
  11. Grosser T, Fries S, Fitzgerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. The Journal of Clinical Investigation. 2006;116:4-15. https://doi.org/10.1172/JCI27291
  12. Grosser T, Yu Y, Fitzgerald G. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annual Review of Medicine. 2010;61:17-33. https://doi.org/10.1146/annurev-med-011209-153129
  13. Brownstein J, Sordo M, Kohane I, Mandl K. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PloS One. 2007;2:840. https://doi.org/10.1371/journal.pone.0000840
  14. United States Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Meeting February 10—11. [Accessed 05/23/2017]. Food and Drug Administration. 2014.
  15. Bort R, Ponsoda X, Carrasco E, Gomez-Lechon MJ, Castell JV. Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996;24:834-841.
  16. Saraf S. Aceclofenac: A potent non steroidal anti-inflammatory drug in latest reviews. Latest Rev. 2006;4(3):119-124.
  17. Lidbury P, Vojnovic I, Warner T. COX-2/COX-1 selectivity of aceclofenac in comparison with celecoxib and rofecoxib in the human whole blood assay. Osteoarthritis Cartilage. 2000;8(suppl B):40.
  18. Gonzalez E, de la Cruz C, de Nicolas R, Egido J, Herrero-Beaumont G. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions. 1994;41:171-178.
  19. Reginster J, Paul I, Henrotin Y. What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies? Rev Med Liege. 2001;56(7):484-488.
  20. Blot L, Marcelis A, Devogelaer J, Manicourt D. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000;131(7):1413-1421. https://doi.org/10.1038/sj.bjp.0703710
  21. Dingle J. The effects of NSAID on the matrix of human articular cartilages. Z Rheum. 1999;58(3):125-129.
  22. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004;5:1347-1357. https://doi.org/10.1517/14656566.5.6.1347
  23. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61:1351-1378. https://doi.org/10.2165/00003495-200161090-00012
  24. Letzel H, Lamarca R, Raber A, Fortea J. The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2006;129:162-168. https://doi.org/10.1016/j.ejogrb.2006.01.004
  25. Zhivolupov SA, Samartsev IN, Nazhmudinov RZ, Yakovlev EV. Clinical trial KAMELIA: the comparative study of safety and efficacy of aceclofenac and meloxicam in short-term treatment of patients with back pain. Effectivnaya Pharmacoterapiya. 2018;20:3-13. (In Russ.)
  26. Patel P, Patel T. Efficacy and safety of aceclofenac in osteoarthritis. Eur J Rheumatol. 2017;4:11-18. https://doi.org/10.5152/eurjrheum.2017.160080
  27. Grishaeva TP, Balabanova RM. Experience of application Airtal (aceclofenac) in the treatment of rheumatic diseases. Trudnyi Patsient. 2005;2:29-31. (In Russ.)
  28. Osipok NV, Chernykh SYu, Zlobina TI. Clinical efficacy and tolerability of aceclofenac (Airtal) in chronic diseases of the joints. Sovremennye Problemy Revmatologii. 2005;2:204-208. (In Russ.)
  29. Starikov AS, Penina GO. The use of aceclofenac in the treatment of acute vertebrogenic compression-ischemic syndrome. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(8):57-59. (In Russ.)
  30. Zamyatina EA, Bagirova GG. The use of meloxicam (Movalis) and aceclofenac (Airtal) in the elderly with osteoarthritis. Izvestiya Vysshikh Uchebnykh Zavedenii. 2012;1:40-46. (In Russ.)
  31. Sharapova EP, Taskina EA, Raskina TA. Aceclofenac in the treatment of osteoarthritis. Lechashchii Vrach. 2012;8:90-94. (In Russ.)
  32. Parfenov VA, Gerasimova ON. Nonspecific back pain in outpatient practice, the use of aertal and midocalm. Spravochnik Poliklinicheskogo Vracha. 2013;1:34-37. (In Russ.)
  33. Karateev AE, Denisov LN, Markelova EI. The results of clinical research AEROPLAN (analysis of the effectiveness and risk of complications in the treatment of arthritis by aceclofenac and nimesulide). Consilium Medicum. 2013;15(2):48-53. (In Russ.)
  34. Lobanova EV, Goncharova OM, Ryabtseva EA. Opportunities aceclofenac (airtal) for treatment of patients with osteoarthritis. Amurskii Meditsinskii Zhurnal. 2014;4(8):29-31. (In Russ.)
  35. Isaenko SS, Peshkova SYu. Experience in the application of aceclofenac in the complex treatment of pain syndrome in patients with pain in the lower back. Sovremennye Problemy Revmatologii. 2014;6:53-56. (In Russ.)
  36. Sharapova EP, Kashevarova NG., Anikin S. The use of new aceclofenac dosage forms in patients with osteoarthrosis in real-life clinical practice. Sovremennaya revmatologiya. Modern Rheumatology Journal. 2014;8(1):73-76. (In Russ.) https://doi.org/10.14412/1996-7012-2014-1-73-76
  37. Myakotnykh VS, Torgashov MN. Stress-induced pain syndromes and their treatment with the use of a new form of aceclofenac. Klinicheskaya Farmakologiya i Terapiya. 2015;2:26-30. (In Russ.)
  38. Zagorodnii NV, Ivashkin AN, Zakirova AR, Skipenko TO. The use of ceclofenac (Airtal) in the early stages of gonarthrosis. Consilium Medicum. 2016;8:42-45. (In Russ.)
  39. Gontarenko NV, Tsurgan AV, Karateev AE. Treatment for acute/subacute musculoskeletal pain, by using an algorithm for stepwise choice of analgesic drugs and for monitoring their efficacy: preliminary data of the analgesic treatment using systemic algorithm (ALISA) program. Sovremennaya Revmatologiya. 2016;10(4):35-40. (In Russ.) https://doi.org/10.14412/1996-7012-2016-4-35-40
  40. Yang J, Suk K, Lee B, Jung W, Kang Y, Kim J, Kim H, Lee H, Moon S. Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. Yonsei Medical Journal. 2017;58(3):637. https://doi.org/10.3349/ymj.2017.58.3.637
  41. Catella-Lawson F. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. The Journal of Pharmacology and Experimental Therapeutics. 1999;289:735-741.
  42. McAdam BF. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:272-277. https://doi.org/10.1073/pnas.96.1.272
  43. Fitzgerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. The New England Journal of Medicine. 1984;310:1065-1068. https://doi.org/10.1056/NEJM198404263101701
  44. Fitzgerald DJ. Platelet activation in unstable coronary disease. The New England Journal of Medicine. 1986;315:983-989.
  45. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Puré E, Funk CD, Fitzgerald GA. Vascular COX-2 modulates blood pressure and thrombosis in mice. Science Translational Medicine. 2012;4:132-154. https://doi.org/10.1126/scitranslmed.3003787
  46. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. The Journal of Clinical Investigation. 2004;114:784-794. https://doi.org/10.1172/JCI21446
  47. Egan K, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954-1957. https://doi.org/10.1126/science.1103333
  48. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. The Journal of Clinical Investigation. 2002;110:61-69. https://doi.org/10.1172/JCI14752
  49. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:199-233. https://doi.org/10.1378/chest.08-0672
  50. Capone ML, Tacconelli S, Sciulli MG, Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109:1468-1471.
  51. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563-7568. https://doi.org/10.1073/pnas.96.13.7563
  52. Coxib and traditional NSAID Trialists’ Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-779. https://doi.org/10.1016/S0140-6736(13)60900-9
  53. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Medicine. 2011;8:1001098. https://doi.org/10.1371/journal.pmed.1001098
  54. Lapi F, Piccinni C, Simonetti M, Lora Aprile P, Cricelli I, Fanelli A, Cricelli C, Lapi F. Nonsteroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med. 2016;11:49-59. https://doi.org/10.1002/phar.1646
  55. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387:2093-2105. https://doi.org/10.1016/S0140-6736(17)31744-0
  56. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol. 2010;55:1002-1006. https://doi.org/10.1016/j.jacc.2009.11.046
  57. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490-496. https://doi.org/10.1001/archinte.165.5.IOI50013
  58. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(suppl 3):2. https://doi.org/10.1186/ar4174
  59. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289-300. https://doi.org/10.7326/0003-4819-121-4-199408150-00011
  60. Whelton A, White WB, Bello AE, Puma JA, Fort JG.; SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients over 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963. https://doi.org/10.1016/s0002-9149(02)02661-9
  61. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens. 2000;13:1161-1167. https://doi.org/10.1016/s0895-7061(00)01204-8
  62. García-Poza P, de Abajo FJ, Gil MJ, Chacón A, Bryant V, García-Rodríguez LA. Risk of ischaemic stroke associated with non-steroidal anti-inflammatory drugs and paracetamol: a population-based case-control study. J Thromb Haemost. 2015;13:708-718. https://doi.org/10.1111/jth.12855
  63. Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contribute to tolerability. CuOP Med Res Opin. 2007;23(12):2985-2995. https://doi.org/10.1185/030079907X242584
  64. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Intern Med. 1996;156:1530-1536.
  65. Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993—2002: a population-based cohort study. Am J Gastroenterol. 2006;101(5):945-953. https://doi.org/10.1111/j.1572-0241.2006.00518.x
  66. Karateev AE, Nasonov EL, Ivashkin VT, Martynov AI, Yakhno NN, Arutyunov GP, Alekseeva LI, Abuzarova GR, Evseev MA, Kukushkin ML, Kopenkin SS, Lila AM, Lapina TL, Novikova DS, Popkova TV, Rebrov AP, Skorobogatykh KV, Chichasova NV. Rational use of nonsteroidal anti-inflammatory drugs. clinical guidelines. Rheumatology Science and Practice. 2018;56:1-29. (In Russ.) https://doi.org/10.14412/1995-4484-2018-1-29
  67. Hunt R, Lazebnik BL, Marakhouski CY, Manuc M, Gn R, Aye SK, Garg A. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G. Euroasian Journal of Hepato-Gastroenterology. 2018;8(2):148-160. https://doi.org/10.5005/jp-journals-10018-1281

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.